![Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with](https://pbs.twimg.com/media/FUaqFoRWAAExWwk.jpg:large)
Brian Skorney on Twitter: "Magrolimab + aza data out. CR rate in 2019 was 50% in high risk MDS. Down to 42% in 2020. Now 33% today. Contrast with 32% CR with
![JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy](https://www.mdpi.com/jcm/jcm-10-02107/article_deploy/html/images/jcm-10-02107-g001.png)
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
![Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/66c02659-5955-4f22-9f2c-641b8329a728/imj15934-fig-0003-m.jpg)
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library
![Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society](https://www.lls.org/sites/default/files/styles/image_component/public/2021-08/Forty%20Seven_D8_thumb%20360x200_2.png?itok=DN1n6cG3)
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society
![Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram](https://www.researchgate.net/publication/338745998/figure/tbl3/AS:850126197231624@1579697288675/Efficacy-of-magrolimab-azacitidine-in-untreated-AML-and-MDS-patients_Q320.jpg)
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
![Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert](https://www.cliniexpert.com/attachment/20200210/2d37713285e0464cb040d18ba735ffc9.png)
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
![Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-020-00361-x/MediaObjects/41392_2020_361_Fig1_HTML.png)
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
![A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2022-0975/asset/images/medium/figure1.gif)
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
![Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes](https://www.mdpi.com/cells/cells-11-02249/article_deploy/html/images/cells-11-02249-g001.png)